GlassScriptPhysician profile
Mehool A Patel
NPI 1275617904
$1,585.28
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $849 · 2023: $373 · 2024: $197 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.11 |
| Education | $250.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $571.59 | 2022-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $134.34 | 2022-2024 | Enhertu, Imfinzi |
| Astellas Pharma US INC | $124.98 | 2024 | |
| Legend Biotech USA INC. | $124.33 | 2025 | Carvykti |
| Abbvie INC. | $114.57 | 2022-2023 | |
| Seagen INC. | $114.22 | 2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $50.35 | 2022-2023 | Opdualag, Opdivo |
| Aveo Pharmaceuticals, INC. | $49.31 | 2022-2023 | Fotivda |
| Novartis Pharmaceuticals Corporation | $44.87 | 2022-2023 | |
| Genentech USA, INC. | $44.84 | 2022-2023 | Alecensa, Tecentriq |
| Amgen INC. | $40.66 | 2022-2023 | Lumakras |
| Pfizer INC. | $40.47 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $33.05 | 2022 | |
| Merck Sharp & Dohme LLC | $21.75 | 2023 | Keytruda, Lynparza |
| Genzyme Corporation | $17.87 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $17.33 | 2022 | |
| Glaxosmithkline, LLC. | $14.77 | 2025 | Jemperli |
| G1 Therapeutics, INC. | $13.50 | 2023 | Cosela |
| Epizyme, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehool Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.